FindTrial
Sign In

225Ac-J591

DRUG4 trials

Sponsors

Weill Medical College of Cornell University

Conditions

Prostate Cancer

Early Phase 1

Re-treatment 225Ac-J591 for mCRPC
CompletedNCT04576871
Weill Medical College of Cornell UniversityProstate Cancer
Start: 2020-10-29End: 2024-05-31Updated: 2025-08-28

Phase 1

Phase I Trial of 225Ac-J591 in Patients With mCRPC
CompletedNCT03276572
Weill Medical College of Cornell UniversityProstate Cancer
Start: 2017-10-10End: 2023-09-01Updated: 2024-06-13
Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer
Active, not recruitingNCT04886986
Weill Medical College of Cornell UniversityProstate Cancer
Start: 2021-06-30End: 2029-12-01Updated: 2026-03-31
Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer
Active, not recruitingNCT04946370
Weill Medical College of Cornell UniversityProstate Cancer
Start: 2021-08-12End: 2029-12-01Updated: 2026-02-03

Related Papers

PSMA-targeted actinium-225 therapy in metastatic castration-resistant prostate cancer (mCRPC): Baseline and follow-up PSMA PET parameters associated with outcomes.
Journal of Clinical Oncology2025-05-281 citations
Mature phase 1 follow up of alpha emitter 225Ac-J591 with 177Lu-PSMA-I&T in advanced prostate cancer.
Journal of Clinical Oncology2025-02-10
Baseline Imaging Derived Factors of Response Following [225Ac]Ac‐J591 Therapy in Metastatic Castration‐Resistant Prostate Cancer: A Lesion Level Analysis
The Prostate2025-01-231 citations
Phase I dose-escalation results of prostate-specific membrane antigen-targeted radionuclide therapy (PSMA-TRT) with alpha-radiolabeled antibody <sup>225</sup>Ac-J591 and beta-radioligand <sup>177</sup>Lu-PSMA I&amp;T.
Journal of Clinical Oncology2023-06-0110 citations
Phase I results of a phase I/II study of pembrolizumab and AR signaling inhibitor (ARSI) with 225Ac-J591.
Journal of Clinical Oncology2023-02-207 citations
AlphaBet: Combination of Radium-223 and [177Lu]Lu-PSMA-I&amp;T in men with metastatic castration-resistant prostate cancer (clinical trial protocol)
Frontiers in Medicine2022-11-1840 citations
Abstract CT143: Results of combined targeting of prostate-specific membrane antigen (PSMA) with alpha-radiolabeled antibody 225Ac-J591 and beta-radiolabeled ligand 177Lu-PSMA I&amp;T: preclinical and initial phase 1 clinical data in patients with metastatic castration-resistant prostate cancer (mCRPC)
Cancer Research2022-06-155 citations
Abstract 1264: CTC-based biomarker analysis and correlation with clinical response to PSMA-TRT in mCRPC
Cancer Research2022-06-15
Phase I/II trial of pembrolizumab and AR signaling inhibitor +/- 225Ac-J591 for chemo-naive metastatic castration-resistant prostate cancer (mCRPC).
Journal of Clinical Oncology2022-02-168 citations
Assessment of patient-reported outcomes (PROs) and longer-term adverse events (AEs) in phase I study of <sup>225</sup>Ac-J591-PSMA for metastatic castration-resistant prostate cancer (mCRPC).
Journal of Clinical Oncology2022-02-162 citations
Phase I study of <sup>225</sup>Ac-J591 for men with metastatic castration-resistant prostate cancer (mCRPC).
Journal of Clinical Oncology2021-05-2030 citations
Abstract CT122: Phase I dose-escalation study of prostate-specific membrane antigen (PSMA)-targeted alpha emitter 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC)
Cancer Research2020-08-15
Phase I dose-escalation study of PSMA-targeted alpha emitter <sup>225</sup>Ac-J591 in men with metastatic castration-resistant prostate cancer (mCRPC).
Journal of Clinical Oncology2020-05-2010 citations
Dose-escalation results of a phase I study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC).
Journal of Clinical Oncology2020-02-1924 citations
Association of noninvasive, radiographic measurement of prostate-specific membrane antigen (PSMA) expression with response to PSMA-targeted radionuclide therapy (TRT).
Journal of Clinical Oncology2019-05-202 citations
Phase I dose-escalation study of <sup>225</sup>Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC).
Journal of Clinical Oncology2018-02-2022 citations